In this issue:
Osimertinib delays progression in EGFR-mutated advanced NSCLC
Anamorelin for cancer cachexia
Pulse/continuous-dose erlotinib in EGFR-mutant NSCLC with CNS disease
Postoperative RT and chemotherapy sequencing in NSCLC
IMPRESS: Overall survival and biomarker analyses
Nivolumab vs docetaxel in advanced NSCLC: 2-year data
KEYNOTE-028: Pembrolizumab in SCLC
Pasireotide + everolimus in lung and thymic carcinoids
Can CTCs assess PD-L1 status in advanced NSCLC?
IMPOWER150: Primary PFS and safety analyses
Please login below to download this issue (PDF)